Roxadustat vs BYM338
Head-to-head comparison of Roxadustat (Roxadustat (FG-4592), hypoxia-inducible factor prolyl hydroxylase inhibitor) and BYM338 (Bimagrumab (BYM338)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Roxadustat | BYM338 |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| Full Name | Roxadustat (FG-4592), hypoxia-inducible factor prolyl hydroxylase inhibitor | Bimagrumab (BYM338) |
| Molecular Weight | 352.35 Da | ~148 kDa |
| Half-Life | ~12-16 h | ~2-3 weeks |
| Amino Acids | N/A | N/A |
| Typical Dose | 70-100 mg orally three times weekly | 10-30 mg/kg IV in trials |
| Route | Oral | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 180 | 140 |
| Research Status | Clinical | Clinical |
Roxadustat Benefits
- ✓induces endogenous EPO
- ✓improves iron handling
- ✓raises hemoglobin
- ✓may improve exercise tolerance
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
Roxadustat Dosing
70-100 mg orally 3x weekly|Titrate by hemoglobin response|Monitor iron indices regularly
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
Roxadustat Side Effects
- ⚠nausea
- ⚠hypertension
- ⚠thrombotic events
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
Research Overview
Roxadustat
Large clinical studies support roxadustat for anemia, especially in chronic kidney disease populations. Direct VO2 max enhancement data in healthy athletes are limited, so its performance effects remain mostly inferential.
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.